Chemotherapeutic effects of luteolin on radio-sensitivity enhancement and interleukin-6/signal transducer and activator of transcription 3 signaling repression of oral cancer stem cells

Journal of the Formosan Medical Association

Volumn 115, Issue 12, 2016, Pages 1032-1038

  Tu, Dom Gene ^a,b,c   Lin, Wei Ting ^a   Yu, Cheng Chia ^d,e   Lee, Shiuan Shinn ^d   Peng, Chih Yu ^d,e   Lin, Taichen ^d,e   Yu, Chuan Hang ^d,e  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cancer stem cells; luteolin; oral carcinomas; radio sensitivity

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; HERMES ANTIGEN; INTERLEUKIN 6; LUTEOLIN; STAT3 PROTEIN; CD44 PROTEIN, HUMAN; ISOENZYME; RETINAL DEHYDROGENASE; STAT3 PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CLONOGENESIS; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUTH CANCER; MTT ASSAY; RADIOSENSITIVITY; STEM CELL SELF-RENEWAL; WESTERN BLOTTING; CARCINOGENESIS; DRUG EFFECTS; METABOLISM; MOUTH NEOPLASMS; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

ANTIGENS, CD44; CARCINOGENESIS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; ISOENZYMES; LUTEOLIN; MOUTH NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RETINAL DEHYDROGENASE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85001960774     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2016.08.009     Document Type: Article

References (34)

1. 1 Visvader, J.E., Lindeman, G.J., Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8 (2008), 755–768.
2. 2 Hu, F.W., Tsai, L.L., Yu, C.H., Chen, P.N., Chou, M.Y., Yu, C.C., Impairment of tumor-initiating stem-like property and reversal of epithelial–mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res 56 (2012), 1247–1258.
3. 3 Yu, C.C., Tsai, L.L., Wang, M.L., Yu, C.H., Lo, W.L., Chang, Y.C., et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 73 (2013), 3425–3440.
4. 4 Liu, C.M., Peng, C.Y., Liao, Y.W., Lu, M.Y., Tsai, M.L., Yeh, J.C., et al. Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction. J Formos Med Assoc, 2016 Feb 12 pii: S0929-6646(16)00028-0. doi: 10.1016/j.jfma.2016.01.004. [Epub ahead of print].
5. 5 Yu, C.C., Chen, P.N., Peng, C.Y., Yu, C.H., Chou, M.Y., Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget 7 (2016), 20180–20192.
6. 6 Chiou, S.H., Yu, C.C., Huang, C.Y., Lin, S.C., Liu, C.J., Tsai, T.H., et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14 (2008), 4085–4095.
7. 7 Chen, Y.S., Wu, M.J., Huang, C.Y., Lin, S.C., Chuang, T.H., Yu, C.C., et al. CD133/Src axis mediates tumor initiating property and epithelial–mesenchymal transition of head and neck cancer. PLoS One, 6, 2011, e28053.
8. 8 Wu, M.J., Jan, C.I., Tsay, Y.G., Yu, Y.H., Huang, C.Y., Lin, S.C., et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer, 9, 2010, 283.
9. 9 Yu, C.C., Hu, F.W., Yu, C.H., Chou, M.Y., Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head Neck 38 (2016), E231–E238.
10. 10 Lin, Y., Shi, R., Wang, X., Shen, H.M., Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 8 (2008), 634–646.
11. 11 Ding, S., Hu, A., Hu, Y., Ma, J., Weng, P., Dai, J., Anti-hepatoma cells function of luteolin through inducing apoptosis and cell cycle arrest. Tumour Biol 35 (2014), 3053–3060.
12. 12 Cai, X., Ye, T., Liu, C., Lu, W., Lu, M., Zhang, J., et al. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol In Vitro 25 (2011), 1385–1391.
13. 13 Chang, J., Hsu, Y., Kuo, P., Kuo, Y., Chiang, L., Lin, C., Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalized human hepatoma cell line. Life Sci 76 (2005), 1883–1893.
14. 14 Chian, S., Thapa, R., Chi, Z., Wang, X.J., Tang, X., Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun 447 (2014), 602–608.
15. 15 Ju, W., Wang, X., Shi, H., Chen, W., Belinsky, S.A., Lin, Y., A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71 (2007), 1381–1388.
16. 16 Rao, P.S., Satelli, A., Moridani, M., Jenkins, M., Rao, U.S., Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int J Cancer 130 (2012), 2703–2714.
17. 17 Choi, E.M., Lee, Y.S., Luteolin suppresses IL-1beta-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW982. Food Chem Toxicol 48 (2010), 2607–2611.
18. 18 Dia, V.P., Pangloli, P., Epithelial-to-mesenchymal transition in paclitaxel-resistant ovarian cancer cells is downregulated by luteolin. J Cell Physiol, 2016 [Epub ahead of print].
19. 19 Ruan, J., Zhang, L., Yan, L., Liu, Y., Yue, Z., Chen, L., et al. Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. Mol Med Rep 6 (2012), 232–238.
20. 20 Tsai, L.L., Hu, F.W., Lee, S.S., Yu, C.H., Yu, C.C., Chang, Y.C., Oct4 mediates tumor initiating properties in oral squamous cell carcinomas through the regulation of epithelial–mesenchymal transition. PLoS One, 9, 2014, e87207.
21. 21 Kumar, S., Raina, K., Agarwal, C., Agarwal, R., Silibinin strongly inhibits the growth kinetics of colon cancer stem cell-enriched spheroids by modulating interleukin 4/6-mediated survival signals. Oncotarget 5 (2014), 4972–4989.
22. 22 Chou, M.Y., Hu, F.W., Yu, C.H., Yu, C.C., Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells. Oral Oncol 51 (2015), 31–39.
23. 23 Chen, Y.W., Chen, K.H., Huang, P.I., Chen, Y.C., Chiou, G.Y., Lo, W.L., et al. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 9 (2010), 2879–2892.
24. 24 Li, W.C., Lee, P.L., Chou, I.C., Chang, W.J., Lin, S.C., Chang, K.W., Molecular and cellular cues of diet-associated oral carcinogenesis-with an emphasis on areca-nut-induced oral cancer development. J Oral Pathol Med 44 (2015), 167–177.
25. 25 Yu, C.C., Chen, Y.W., Chiou, G.Y., Tsai, L.L., Huang, P.I., Chang, C.Y., et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 47 (2011), 202–210.
26. 26 Bowman, T., Garcia, R., Turkson, J., Jove, R., STATs in oncogenesis. Oncogene 19 (2000), 2474–2488.
27. 27 Bromberg, J., Stat proteins and oncogenesis. J Clin Invest 109 (2002), 1139–1142.
28. 28 Leeman-Neill, R.J., Seethala, R.R., Singh, S.V., Freilino, M.L., Bednash, J.S., Thomas, S.M., et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) 4 (2011), 230–237.
29. 29 Macha, M.A., Matta, A., Kaur, J., Chauhan, S.S., Thakar, A., Shukla, N.K., et al. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck 33 (2011), 482–489.
30. 30 Tang, Y., Kitisin, K., Jogunoori, W., Li, C., Deng, C.X., Mueller, S.C., et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A 105 (2008), 2445–2450.
31. 31 Marotta, L.L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S.R., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors. J Clin Invest 121 (2011), 2723–2735.
32. 32 Korkaya, H., Liu, S., Wicha, M.S., Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121 (2011), 3804–3809.
33. 33 Korkaya, H., Kim, G.I., Davis, A., Malik, F., Henry, N.L., Ithimakin, S., et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47 (2012), 570–584.
34. 34 Chen, C.C., Chen, W.C., Lu, C.H., Wang, W.H., Lin, P.Y., Lee, K.D., et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 76 (2010), 1214–1224.